Loading...
OTCMELOX
Market cap0kUSD
Dec 20, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-100.00%
IPO
-100.00%
Name

Eloxx Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:ELOX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
77.08%
Rev. gr., 5y
%
Revenues
0k
16,667125,00066,666300,000456,667275,000140,0000200,0000100,00075,00075,0000000000
Net income
-36m
L-45.95%
-3,726,951-2,978,918-3,314,885-3,251,697-4,601,490-5,726,869-13,383,513-7,268,976-5,066,133-6,122,542-9,225,234-18,063,785-8,267,929-5,796,363-21,214,000-47,185,000-50,874,000-34,577,000-66,727,000-36,065,000
CFO
-32m
L-9.02%
-1,893,401-2,115,900-2,530,389-2,031,489-2,405,419-3,962,680-4,743,129-5,391,442-4,386,049-3,902,626-4,868,133-7,344,696-3,676,215-1,925,110-15,935,000-31,367,000-39,391,000-28,166,000-35,001,000-31,845,000

Profile

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
URL
https://www.eloxxpharma.com/
IPO date
Nov 23, 2012
Employees
18
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122017‑062016‑062015‑06
Income
Revenues
Cost of revenue
34,419
66,018
Unusual Expense (Income)
NOPBT
(34,419)
(66,018)
NOPBT Margin
Operating Taxes
2,026
1,259
Tax Rate
NOPAT
(36,445)
(67,277)
Net income
(36,065)
-45.95%
(66,727)
92.98%
Dividends
Dividend yield
Proceeds from repurchase of equity
47,718
BB yield
-3,863.20%
Debt
Debt current
4,692
657
Long-term debt
9,539
14,261
Deferred revenue
Other long-term liabilities
Net debt
(4,976)
(27,350)
Cash flow
Cash from operating activities
(31,845)
(35,001)
CAPEX
(66)
(89)
Cash from investing activities
(66)
2,056
Cash from financing activities
8,812
50,788
FCF
(35,780)
(68,382)
Balance
Cash
19,207
42,268
Long term investments
Excess cash
19,207
42,268
Stockholders' equity
(274,366)
(238,301)
Invested Capital
277,090
274,142
ROIC
ROCE
EV
Common stock shares outstanding
2,166
1,749
Price
1.82
157.72%
0.71
-82.26%
Market cap
3,943
219.20%
1,235
-69.06%
EV
(1,033)
(26,115)
EBITDA
(33,724)
(65,058)
EV/EBITDA
0.03
0.40
Interest
1,949
1,259
Interest/NOPBT